Will identify fully human antibodies against two targets chosen by Novartis
Adimab, a US developer of fully human antibodies, has entered into a research collaboration with Swiss drugmaker Novartis.
Under the agreement, Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Novartis.
Novartis will commercialise antibodies generated from the collaboration and pay upfront payments, preclinical milestones and licensing fees to Adimab.
Adimab is also eligible to receive clinical development milestones and royalties on therapeutic and diagnostic product sales.
This is the fifth major partnership Adimab has announced since launching its antibody discovery platform in 2009.
The firm has also recently received a second milestone payment from its ongoing collaboration with Merck and Co.
‘We are in active discussions with several partners regarding broader unencumbered access and technology transfer,’ said Tillman Gerngross, co-founder and ceo of Adimab.
‘With current announced and unannounced contracts, continued revenue from milestone payments and broad interest around Adimab’s platform, we expect 2010 to be our first profitable year,’ added Errik Anderson, coo of Adimab.